Cannabis and mental illness : a review Darby J. E. Lowe · Julia D. Sasiadek · Alexandria S. Coles · Tony P. George European Archives of Psychiatry and Clinical Neuroscience, 2018, 1-14. Doi : 10.1007/s00406-018-0970-7 Abstract With the increasing push to legalize cannabis in Western nations, there is a need to gage the potential impact of this policy change on vulnerable populations, such as those with mental illness, including schizophrenia, mood, and anxiety disorders. This is particularly important as there are strong motives in these individuals to seek short-term reward (e.g., “getting high”). Nonetheless, data to support the beneficial effects of cannabis use in psychiatric [...]
Lire la suiteCannabis and Depression Daniel Feingold, Aviv Weinstein Advances in Experimental medicine and Biology, 2021, 1264, 67-80. In book : "Cannabinoids and Neuropsychiatric Disorders", Aviv Weinstein 's Lab Doi : 10.1007/978-3-030-57369-0_5 Abstract There is a growing body of evidence pointing to the co-occurrence of cannabis use and depression. There is also some evidence that the use of cannabis may lead to the onset of depression; however, strong evidence points to the inverse association; i.e. that depression may lead to the onset or increase in cannabis use frequency. Observational and epidemiological studies have not indicated a positive long-term effect of cannabis use on the course and outcome of [...]
Lire la suiteCannabidiol as a Treatment for Mood Disorders : A Systematic Review Le cannabidiol comme traitement des troubles de l’humeur : une revue systématique Jairo Vinicius Pinto, MD, Gayatri Saraf, MD, Christian Frysch, MD, Daniel Vigo, MD, DrPH, Kamyar Keramatian, MD, MSc, FRCPC, Trisha Chakrabarty, MD, Raymond W. Lam, MD, Marcia Kauer-Sant’Anna, MD, PhD, and Lakshmi N. Yatham, MBBS, FRCPC The Canadian Journal of Psychiatry /La Revue Canadienne de Psychiatrie, 2020, Vol. 65, (4), 213-227. Doi : 10.1177/0706743719895195 Abstract Objective : To review the current evidence for efficacy of cannabidiol in the treatment of mood disorders. Methods : We systematically searched PubMed, Embase, Web of Science, PsychInfo, Scielo, [...]
Lire la suitePsychedelic Medicines for Mood Disorders Current Evidence and Clinical Considerations Jerome Sarris; Diego Pinzon Rubiano; Kimberley Day; Nicole L. Galvão-Coelho; Daniel Perkins Current Opinion in Psychiatry, 2022, 35, (1), 22-29. doi : 10.1097/YCO.0000000000000759 https://www.medscape.com/viewarticle/964245 Abstract and Introduction Abstract Purpose of Review: Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions. Recent Findings: Serotonergic psychedelics have been found to modulate brain networks underlying various psychiatric disorders, as well promoting neurogenesis and neuroplasticity. Randomized placebo-controlled trials have found psilocybin with psychological support effective at [...]
Lire la suite